Skip to main content

Edge BioSystems Licenses Protein-Refolding Technology from KU Medical Center

NEW YORK, April 20 (GenomeWeb News) - Kansas University Medical Center has given Edge BioSystems a license to manufacture and use a protein-refolding technology that Edge plans to apply to drug discovery and diagnostics, the organizations said today.


Edge sees a "very broad range of applications for this technology," including large-scale functional assays for drug discovery, target validation, high-throughput screening, and possibly structural studies, Omayma Al-Awar, director of sales and marketing for Edge, told GenomeWeb News today. The company believes the technology will be useful to customers in academia and pharmaceutical companies, she added.


Al-Awar declined to disclose financial terms of the license.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.